Song, Qingxiao http://orcid.org/0000-0001-9243-5666
Wang, Xiaoning http://orcid.org/0000-0002-2472-4076
Wu, Xiwei
Kang, Tae Hyuk http://orcid.org/0000-0001-9085-8139
Qin, Hanjun
Zhao, Dongchang
Jenq, Robert R.
van den Brink, Marcel R. M. http://orcid.org/0000-0003-0696-4401
Riggs, Arthur D.
Martin, Paul J. http://orcid.org/0000-0001-9051-1215
Chen, Yuan-Zhong http://orcid.org/0000-0002-9411-1427
Zeng, Defu http://orcid.org/0000-0001-9585-1411
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI066008)
National Cancer Center (R01 CA228465, P30CA033572)
Article History
Received: 11 November 2019
Accepted: 10 January 2021
First Online: 5 February 2021
Competing interests
: R.R.J. is on the scientific advisory board for Seres Therapeutics, Inc., has consulted for Ziopharm Oncology and MicrobiomeDx, and holds patents licensed to Seres Therapeutics, Inc. The other authors have no conflict of interest.